文献速递呼吸衰竭与机械通气儿科与产科急症

阿奇霉素预防早产儿慢性肺病(AZTEC):多中心、双盲、随机、安慰剂对照试验

Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2024-04-25
一句话结论对胎龄<30周、生后72小时内需呼吸支持的早产儿,预防性阿奇霉素未提高无中重度慢性肺病生存率(42% vs 45%,aOR 0.84,95%CI 0.55-1.29,p=0.43),作者认为不能推荐用于临床。

AZTEC是在英国28个三级新生儿重症监护病房开展的多中心、双盲、随机、安慰剂对照试验,纳入胎龄<30周且生后72小时内接受至少2小时无创或有创呼吸支持的早产儿,按1:1随机接受静脉阿奇霉素20 mg/kg/d×3天序贯10 mg/kg×7天或安慰剂。主要终点为矫正胎龄36周时无生理学定义的中重度慢性肺病生存。结果显示干预组166/394(42%)、安慰剂组179/402(45%)达到主要终点(三级校正OR 0.84,95%CI 0.55-1.29,p=0.43),肺部Ureaplasma spp定植未影响疗效。作者认为预防性阿奇霉素不能推荐用于临床实践。

要点

  • 胎龄<30周早产儿预防性静脉阿奇霉素(20 mg/kg/d×3天序贯10 mg/kg×7天)未改善无中重度CLD生存:42% vs 45%,aOR 0.84,95%CI 0.55-1.29,p=0.43。
  • 阿奇霉素组报告7例严重不良事件(5例重度、2例中度),安慰剂组6例(2例重度、2例中度、2例轻度)。
  • 作者结论:预防性阿奇霉素不能推荐用于临床实践。
  • 研究为多中心、双盲、随机、安慰剂对照试验,共796例纳入分析。

适用人群与场景

  • 胎龄<30周早产儿,且生后72小时内接受至少2小时无创呼吸支持(持续气道正压或加温高流量鼻导管)或有创呼吸支持(经气管插管)。
  • 研究在英国28个三级新生儿重症监护病房开展,共796例纳入分析(干预组394例,安慰剂组402例)。

处置流程与药物剂量

  • 干预方案:静脉阿奇霉素20 mg/kg/d,共3天,随后10 mg/kg/d,共7天。
  • 对照:安慰剂。
  • 主要终点评估时间:矫正胎龄36周时评估无生理学定义的中重度慢性肺病生存。

研究设计与关键结果

  • 研究类型:多中心、双盲、随机、安慰剂对照试验;英国28个三级新生儿重症监护病房;2019年10月9日至2022年3月22日招募;1505例合格婴儿中799例(53.1%)随机分配,3例撤回(包括撤回数据使用同意),796例纳入分析。
  • 干预与对照:静脉阿奇霉素20 mg/kg/d×3天序贯10 mg/kg/d×7天 vs 安慰剂;按中心和出生胎龄(<28周 vs ≥28周)分层,1:1随机,随机区组大小为4。
  • 主要终点:矫正胎龄36周时无生理学定义的中重度慢性肺病生存,干预组166/394(42%)vs 安慰剂组179/402(45%),三级校正OR 0.84(95%CI 0.55-1.29),p=0.43。
  • 不良事件:阿奇霉素组报告7例严重不良事件(5例重度、2例中度),安慰剂组6例(2例重度、2例中度、2例轻度),由当地主要研究者评估。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机、安慰剂对照试验(RCT)。
  • 作者结论:预防性使用阿奇霉素未改善无生理学定义慢性肺病生存,无论Ureaplasma spp定植状态,不能推荐用于临床实践。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为:预防性阿奇霉素不能推荐用于临床实践,因其未改善胎龄<30周早产儿无中重度慢性肺病生存。
  • 适用人群:胎龄<30周、生后72小时内需至少2小时无创或有创呼吸支持的早产儿;不适用于该人群之外的患儿。
  • 肺部Ureaplasma spp定植状态不影响疗效,不应据此选择预防性阿奇霉素(作者结论)。

指南或共识出处

  • AZTEC试验(ISRCRN 11650227),发表于Lancet Respiratory Medicine;资助:UK National Institute for Health and Care Research。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Systematic reviews have reported conflicting evidence on whether macrolide antibiotics reduce rates of chronic lung disease of prematurity (CLD) in at-risk preterm infants born at less than 30 weeks' gestation, including in those colonised with pulmonary Ureaplasma spp. Since an adequately powered trial has been lacking, we aimed to assess if the macrolide azithromycin improved survival without the development of physiologically defined moderate or severe CLD in preterm infants.

METHODS: AZTEC was a multicentre, double-blind, randomised, placebo-controlled trial conducted in 28 tertiary neonatal intensive care units in the UK. Infants were eligible if they were born at less than 30 weeks' gestation and had received at least 2 h of either non-invasive (continuous positive airway pressure or humidified high flow nasal cannula therapy) or invasive respiratory support (via endotracheal tube) within 72 h of birth. Eligible infants were randomly allocated in a 1:1 ratio using random permuted blocks of four to receive either intravenous azithromycin at 20 mg/kg per day for 3 days followed by 10 mg/kg for 7 days, or to placebo. Allocation was stratified by centre and gestational age at birth (<28 weeks vs ≥28 weeks). Azithromycin and placebo vials were encased in tamper-evident custom cardboard cartons to ensure masking for clinicians, parents, and the research team. The primary outcome was survival without development of physiologically defined moderate or severe CLD at 36 weeks' postmenstrual age. Outcomes and safety were analysed on an intention-to-treat basis (all randomly allocated infants, regardless of any post-randomisation events). The study was registered with ISRCRN (11650227) and is closed.

FINDINGS: Infants were recruited between Oct 9, 2019, and March 22, 2022. 799 (53·1%) of 1505 eligible infants underwent random allocation; three infants were withdrawn, including consent to use their data, leaving 796 infants for analysis. Survival without moderate or severe CLD occurred in 166 (42%) of 394 infants in the intervention group and 179 (45%) of 402 in the placebo group (three-level adjusted OR [aOR] 0·84, 95% CI 0·55-1·29, p=0·43). Pulmonary Ureaplasma spp colonisation did not influence treatment effect. Overall, seven serious adverse events were reported for the azithromycin group (five graded as severe, two as moderate), and six serious adverse events were reported in the placebo group (two severe, two moderate, and two mild), as assessed by the local principal investigators.

INTERPRETATION: Since prophylactic use of azithromycin did not improve survival without development of physiologically-defined CLD, regardless of Ureaplasma spp colonisation, it cannot be recommended in clinical practice.

FUNDING: UK National Institute for Health and Care Research.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Lowe J, Gillespie D, Aboklaish A, et al. Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Respir Med. 2024. PMID: 38679042. doi:10.1016/S2213-2600(24)00079-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。